Oncobiologics Net Income 2015-2021 | OTLK

Oncobiologics net income from 2015 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Oncobiologics Annual Net Income
(Millions of US $)
2021 $-53
2020 $-49
2019 $-36
2018 $-48
2017 $-40
2016 $-63
2015 $-53
2014 $-21
2013 $-14
Oncobiologics Quarterly Net Income
(Millions of US $)
2021-09-30 $-13
2021-06-30 $-12
2021-03-31 $-13
2020-12-31 $-14
2020-09-30 $-10
2020-06-30 $-3
2020-03-31 $-17
2019-12-31 $-18
2019-09-30 $-10
2019-06-30 $-5
2019-03-31 $-11
2018-12-31 $-10
2018-09-30 $-13
2018-06-30 $-9
2018-03-31 $-9
2017-12-31 $-18
2017-09-30 $-8
2017-06-30 $-5
2017-03-31 $-8
2016-12-31 $-19
2016-09-30 $-11
2016-06-30 $-30
2016-03-31 $-5
2015-12-31 $-18
2015-09-30 $-17
2015-06-30 $-12
2015-03-31 $-15
2014-12-31 $-7
2014-09-30
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.298B $0.008B
Outlook Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focuses on developing ONS-5010 which is a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration which is in clinical stage. Outlook Therapeutics Inc., formerly known as Oncobiologics Inc., is based in Cranbury, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.122B 9.11
Bio-Rad Laboratories (BIO.B) United States $18.677B 37.90
QIAGEN (QGEN) Netherlands $11.053B 18.72
Biohaven Pharmaceutical Holding (BHVN) United States $8.002B 0.00
Emergent Biosolutions (EBS) United States $2.809B 10.10
Arcus Biosciences (RCUS) United States $2.516B 0.00
Myovant Sciences (MYOV) United Kingdom $1.432B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.186B 0.00
Zymeworks (ZYME) Canada $0.697B 0.00
Ambrx Biopharma (AMAM) United States $0.230B 0.00
SQZ Biotechnologies (SQZ) United States $0.229B 0.00
Enzo Biochem (ENZ) United States $0.160B 20.69